402 related articles for article (PubMed ID: 8666572)
1. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena S; Wang D; Bystritsky A; Baxter LR
J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
[TBL] [Abstract][Full Text] [Related]
2. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
4. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
[TBL] [Abstract][Full Text] [Related]
5. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.
Pfanner C; Marazziti D; Dell'Osso L; Presta S; Gemignani A; Milanfranchi A; Cassano GB
Int Clin Psychopharmacol; 2000 Sep; 15(5):297-301. PubMed ID: 10993132
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Ringold AL; Elliott MA
J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
Arias Horcajadas F; Soto JA; García-Cantalapiedra MJ; Rodríguez Calvin JL; Morales J; Salgado M
Actas Esp Psiquiatr; 2006; 34(3):147-52. PubMed ID: 16736387
[TBL] [Abstract][Full Text] [Related]
8. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
Nakamae T
Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
[TBL] [Abstract][Full Text] [Related]
9. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
10. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
Stein DJ; Bouwer C; Hawkridge S; Emsley RA
J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814
[TBL] [Abstract][Full Text] [Related]
11. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
Foa EB; Simpson HB; Rosenfield D; Liebowitz MR; Cahill SP; Huppert JD; Bender J; McLean CP; Maher MJ; Campeas R; Hahn CG; Imms P; Pinto A; Powers MB; Rodriguez CI; Van Meter PE; Vermes D; Williams MT
J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
[TBL] [Abstract][Full Text] [Related]
12. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
Ammar G; Naja WJ; Pelissolo A
Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
[TBL] [Abstract][Full Text] [Related]
13. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.
Tundo A; Salvati L; Cieri L; Balestrini V; Di Spigno D; Orazi F; Iommi M; Necci R
Int J Psychiatry Clin Pract; 2022 Nov; 26(4):395-400. PubMed ID: 35323098
[TBL] [Abstract][Full Text] [Related]
14. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
Wheaton MG; Rosenfield D; Foa EB; Simpson HB
J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
[TBL] [Abstract][Full Text] [Related]
15. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology.
Agid O; Lerer B
J Clin Psychiatry; 1999 Jan; 60(1):55-6. PubMed ID: 10074882
[No Abstract] [Full Text] [Related]
16. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
Denys D; de Geus F; van Megen HJ; Westenberg HG
J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
[TBL] [Abstract][Full Text] [Related]
17. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Hollander E; Baldini Rossi N; Sood E; Pallanti S
Int J Neuropsychopharmacol; 2003 Dec; 6(4):397-401. PubMed ID: 14604454
[TBL] [Abstract][Full Text] [Related]
18. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle CJ; Fleischmann RL; Epperson CN; Wasylink S; Leckman JF; Price LH
J Clin Psychiatry; 1995 Nov; 56(11):526-8. PubMed ID: 7592506
[TBL] [Abstract][Full Text] [Related]
19. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.
McLean CP; Zandberg LJ; Van Meter PE; Carpenter JK; Simpson HB; Foa EB
J Clin Psychiatry; 2015 Dec; 76(12):1653-7. PubMed ID: 26613263
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
